[Steroid-resistant focal segmental glomerulosclerosis treated with cascade plasmafiltration and rituximab] (original) (raw)

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018

Abstract

A 39-year man with primary steroid resistant focal segmental glomerulosclerosis (FSGS) was treated with mycophenolate mofetil and ACE-inhibitors. After six months a different therapeutics approach was mandatory due to the worsening of renal function and the relapse of proteinuria at the nephrotic range. The combination of cascade plasmafiltration and single dose of rituximab (375 mg/m²) achieved clinical remission and improved renal function in six months follow up. Cascade plasmafiltration in association with rituximab can be considered as a salvage method for primary steroid-resistant FSGS. Clinical trials should be carried out for protocol approval.

Sara Dominijanni hasn't uploaded this paper.

Let Sara know you want this paper to be uploaded.

Ask for this paper to be uploaded.